Amwill Health Care Regulatory Approval

Dividend

Amwill Health Care Dividend

Amwill Health Care's board declared an interim dividend of Rs.0.05 per equity share for FY 2026-27 on 23 October 2026. The record date is 30 October 2026 and payment is proposed by 22 November 2026.

Financial Results

Amwill Health Care H1 FY27 Results: Net Profit ₹3.7 Cr, Down 50.7% YoY

Amwill Health Care Ltd reported revenue from operations of ₹22.6 Cr (-7.0% YoY) and net profit of ₹3.7 Cr (-50.7% YoY) for H1 FY27.

Key figure

Net profit ₹3.7 Cr · -50.7% YoY

Board Meeting Date

Amwill Health Care Board Meeting Date

Amwill Health Care has scheduled a board meeting for October 23, 2026, to review H1 financial results and consider declaring an interim dividend.

Other Announcement

Amwill Health Care Other Announcement

This filing is a standard quarterly Shareholding Pattern submission in accordance with SEBI Regulation 31(1)(b) for Amwill Health Care Ltd as of September 30, 2026.

Acquisition

Amwill Health Care Acquisition Worth ₹3 Cr

Amwill Health Care Limited approved investments of ₹3 Crore into two Alternative Investment Funds. The company will invest ₹1.50 Crore each in Vivriti Vihaan Trust and Neo Income Plus Fund III.

Value

₹3.00 Cr

Execution

Ensuing month(s)

Management Change

Amwill Health Care Management Change

Amwill Health Care Ltd re-appointed Mr. Tarun Gandhi and Mr. Anand Gandhi as Managing Directors for a five-year term, effective January 27, 2027.

Execution

5 years

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.